Acticor Biotech
Created in 2013
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
410 4,189Activities
Technologies
Entity types
Location
29 Rue du Faubourg Saint-Jacques, 75014 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 34
SIREN
798483285Engaged corporates
14
11 6Added in Motherbase
6 years, 1 month ago
deeptech Value proposition
To treat the acute phase of ischemic stroke !
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.
Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.
However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.
This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
biotechnology, monoclonal antibody, drug development, thrombosis, stroke, TIA, Stroke, AVC, and healthcareOriginal language
To treat the acute phase of ischemic stroke !
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.
Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.
However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.
This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
To safely treat the acute phase of ischemic stroke
https://www.acticor-biotech.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Fondation Adolphe de Rothschild NGO, Think Tank, Hospitals and Health Care | Fondation Adolphe de Rothschild NGO, Think Tank, Hospitals and Health Care | Not capitalistic Partnership Event 2 Dec 2020 10 Jun 2024 | | |
 Genopole Biotechnology, Biotechnology Research | Genopole Biotechnology, Biotechnology Research | Other 23 May 2019 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Not capitalistic Not partnership Event 21 Sep 2021 | | |
 Euronext Finance, Financial Services | Euronext Finance, Financial Services | Not capitalistic Not partnership Event 2 Nov 2021 | | |